Flinton Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Flinton Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,056	Closed	-$351K	–	927
2018 Q3	$351K	Buy	21,056 +12,404	+143%	+$224K	0.01%	594
2018 Q2	$137K	Buy	8,652 +812	+10%	+$12.3K	﹤0.01%	718
2018 Q1	$100K	Buy	+7,840	New	+$113K	﹤0.01%	753

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Flinton Capital Management's ALDR Position: Q4 2018 in Review

Flinton Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 21,056 shares — an estimated $351K sold.

Flinton Capital Management first reported a position in ALDR in Q1 2018 and held it in 3 quarters. The position peaked at $351K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Flinton Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Flinton Capital Management sold 21,056 Alder Biopharmaceuticals shares in Q4 2018, an estimated $351K.
Flinton Capital Management first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 3 quarters.
Flinton Capital Management's Alder Biopharmaceuticals position peaked at $351K in Q3 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Flinton Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.